OROpen Access

Oncology Research

Publication Frequency:Bi-monthly

  • Online


  • on board


About the Journal

Oncology Research publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Indexing and Abstracting

Science Citation Index Expanded (Clarivate Analytics): 2021 Impact Factor: 4.938; Scopus CiteScore (Impact per Publication 2021): 11.8; SNIP (Source Normalized Impact per Paper 2021): 0.898; Journal Citation Report/Science Edition (JCR): Q2 (Oncology); etc.

From Volume 29, Number 2, Oncology Research is published by Tech Science Press. To access the past issues of Oncologie Research, please visit Ingenta Connect (https://www.ingentaconnect.com/content/tsp/or).

The COVID-19 epidemic has caused a delay in the paper publication. We anticipate that we shall return to the regular publication schedule in the next few weeks or even sooner. Please accept our sincere apologies for any inconvenience may have caused.

  • Open Access


    The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer

    Oncology Research, Vol.30, No.3, pp. 99-116, 2022, DOI:10.32604/or.2022.026776
    Abstract Infection with high-risk human papillomavirus (HPV), including HPV-16 and HPV-18, is the main cause of malignancies, such as cervical cancer. Viral oncoproteins encoded by HPV are expressed in HPV-positive cancers and associated with the early cancer stages and the transformation of normal cells. The signaling pathways involved in the transformation of normal cells to cancerous form and the subsequently expressed programmed cell death-ligand 1 (PD-L1) on the surface of the transformed cells lead to a disruption in recognition of tumor cells by the immune cell system, including T lymphocytes and dendritic cells which lead to the development of cervical cancer… More >

    Graphic Abstract

    The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer

  • Open Access


    Treatment options in stage I seminoma

    Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511
    Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with strict follow-up regimens and increased… More >

  • Open Access


    Galectins dysregulation: A way for cancer cells to invade and pervade

    Oncology Research, Vol.30, No.3, pp. 129-135, 2022, DOI:10.32604/or.2022.026838
    Abstract Galectins are sticky molecules that bind to β-galactoside. Their interactions render them essential players in many cellular processes. The imbalance of galectin expression was reported in many diseases. In cancer, galectins interact with the extracellular matrix, evade the immune system, and potentially have broad interactions with blood components. In the last ten years, since 2010, we did focus on galectin research in different cancer types. Our findings showed an interaction between cancer cells and erythrocytes via galectin-4. Moreover, we found that upregulation of galectins was associated with lymph node metastasis in ovarian cancers. Hence, with this, we shortly review some… More >

  • Open Access


    Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective

    Oncology Research, Vol.30, No.3, pp. 137-155, 2022, DOI:10.32604/or.2022.026074
    Abstract Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from E-cadherin to N-cadherin, which is… More >

Share Link

WeChat scan